• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 25, 2023 at 09:32: PM
via To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy. Now, the partners have a clutch of data suggesting their long-acting injectable is popular among patients.

article source
 




Top Bottom
Back
Quote